UBS analyst David Lesne has lowered his price target on Aptive PLC (NYSE: APTV), but he has maintained his Buy recommendation for the stock. The new price is $150.00, down from $163.00.
The company is engaged in the business of research, development, and manufacture of active pharmaceutical ingredients (APIs) for the pharmaceutical industry. It operates through two segments: API and Contract Manufacturing. The API segment includes:
– Discovery, lead optimization, and scale-up of active pharmaceutical ingredients (API).
– Manufacturing of bulk API and active pharmaceutical ingredients (API) products.
– Research and development of new active pharmaceutical ingredients (API).
APTV is a U.K.-based manufacturer of fiber optic communication products. The company produces optical fiber, cable, and components. It also offers services such as installation and maintenance. APTV’s main products are in the telecoms, data, and energy sectors. The company has manufacturing facilities in both Europe and Asia. APTV has a market cap of $26.334 billion. Its stock is traded on the London Stock Exchange.